Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients.
European journal of haematology（2023）
摘要
PD-1 mab combined with Rituximab could be a potential treatment option for r/r DLBCL with manageable safety profile.
更多查看译文
关键词
B2M, diffuse large B-cell lymphoma, PD-1 monoclonal antibody, Rituximab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要